Stock Track | Novo Nordisk Soars Over 5% Pre-Market on Promising Obesity Drug Trial Results

Stock Track

Jan 24, 2025

Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.

The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.

The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1120996242"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120996242\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120996242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-24 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120996242","market":"us","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Soars Over 5% Pre-Market on Promising Obesity Drug Trial Results","media":"Stock Track","content":"<p>Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.</p>\n\n<p>The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.</p>\n\n<p>The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Soars Over 5% Pre-Market on Promising Obesity Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Soars Over 5% Pre-Market on Promising Obesity Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-24 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.</p>\n\n<p>The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.</p>\n\n<p>The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1120996242","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120996242","pubTimestamp":1737714623,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Danish drugmaker Novo Nordisk A/S  surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.The results showe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德(Novo Nordisk)股价盘前飙升逾5%，肥胖症药物试验结果乐观","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.\nThe early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.\nThe results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}